Cargando…
Case report: Successful outcome of treatment using rituximab in an adult patient with refractory minimal change disease and β-thalassemia complicating autoimmune hemolytic anemia
Minimal change disease (MCD) is one of the common causes of idiopathic nephrotic syndrome (INS), accounting for 10–20% of INS in adults. Glucocorticoids are the most commonly used and effective drugs in the treatment of MCD, but there is still a proportion of adult patients with MCD who are characte...
Autores principales: | Zhuang, Jing, Zhao, Zhigang, Zhang, Changrong, Song, Xue, Lu, Chen, Tian, Xuefei, Jiang, Hong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9669371/ https://www.ncbi.nlm.nih.gov/pubmed/36405580 http://dx.doi.org/10.3389/fmed.2022.1059740 |
Ejemplares similares
-
Cold autoimmune hemolytic anemia resolved by rituximab
por: Palombi, Massimiliano, et al.
Publicado: (2010) -
Rituximab Use in Warm and Cold Autoimmune Hemolytic Anemia
por: Murakhovskaya, Irina
Publicado: (2020) -
Resolution of alloimmunization and refractory autoimmune hemolytic anemia in a multi-transfused beta-thalassemia major patient
por: Philip, Joseph, et al.
Publicado: (2014) -
Infectious Complications in Autoimmune Hemolytic Anemia
por: Giannotta, Juri Alessandro, et al.
Publicado: (2021) -
Comprehensive management of refractory autoimmune hemolytic anemia in pediatric beta-thalassemia major patient: A case report
por: William, Vincencius, et al.
Publicado: (2021)